Biotech Startups

Momentum Clinical Research (formerly PCRN) operates a network of 19 clinical research sites across Australia and New Zealand, conducting phase I to IV clinical trials across most therapeutic areas. It partners with pharmaceutical and biotech companies to run studies and recruits local participants as trial volunteers.

1 investor

Momentum TX develops therapeutics targeting the aging process to treat age-related conditions of the central and peripheral nervous systems, with a focus on neurodegeneration. It uses in silico, in vitro, and in vivo methods and proteomics data to identify drug targets that restore protein configurations altered in the aged brain.

1 investor

Monarch Biosciences develops and commercializes medical device and biotechnology products based on Thin Film Nitinol technology.

1 investor

Mondego Bio develops PTPN2 (protein tyrosine phosphatase non-receptor type 2) inhibitors as immuno-oncology therapies, aiming to enhance IFNγ signaling to make tumor cells more susceptible to immune attack. The company focuses on small-molecule cancer immunotherapy drug candidates with oral bioavailability and improved safety profiles.

1 investor

Monomer Bio builds software and automation solutions for biological research and development, serving research labs and biotech companies. The platform integrates lab automation, data management, and AI-driven analytics to accelerate molecular and synthetic biology workflows.

1 investor

Montai is a drug discovery company that combines human biology, chemistry, computational biology, and machine learning to identify connections between chemistry and disease pathways and develop new therapies. It focuses on treating chronic diseases and aims to partner with industry to advance therapies for patients and clinicians.

1 investor

Moondogmushrooms produces liquid mushroom extracts derived from fruiting bodies, marketed as dietary supplements for general wellness and energy. The company emphasizes extraction processes to concentrate beneficial compounds for bioavailability.

1 investor

MoonLake develops treatments for serious inflammatory diseases, focusing on its investigational antibody Sonelokimab targeting the IL-17A and IL-17F pathways. Its clinical programs address skin and joint conditions including hidradenitis suppurativa and psoriatic arthritis.

1 investor

Moonlight AI develops software that uses computer vision on routine whole slide images of blood, bone marrow, and cytology smears to detect genomic aberrations, helping diagnostic laboratories complement and triage molecular testing such as NGS. The platform targets hematology and cytopathology workflows to speed turnaround and expand access to genomic insight for cancer diagnostics.

1 investor

MORF-Bio develops software tools that enable scientists to analyze omics data and manage research workflows. The platform serves bench scientists and biotech researchers who need to process and visualize their own experimental data.

1 investor

Moroxite develops biomaterials for spinal fusion and fracture fixation, including bone mineral granules and injectable bone substitutes intended to reduce reliance on autograft transplantation and lower surgical failure rates. The company, based on orthopedic research from Lund University in Sweden, targets the medical device and orthopedic surgery market.

1 investor

A biopharmaceutical company operating in early drug development, commercialization, and life cycle management within the therapeutics and life sciences industry.

1 investor

Mosaic Biosciences is a biologics discovery company that advances biologic drug candidates from discovery through IND-enabling studies and clinical development, working with partners across multiple therapeutic modalities. Its services span protein design and engineering, antibody discovery, and data science for therapeutic programs.

1 investor

MotionHall provides a software platform combined with strategy consulting for senior biopharma executives, supporting IP portfolio management and business development transactions. It uses a proprietary digital twin of the global biopharma landscape along with data science and industry expertise.

1 investor

MPA Pharma is a pharmaceutical company that manufactures and distributes generic and branded medicines. The company operates across multiple business areas in the healthcare sector.

1 investor

MPM Capital is a venture capital and life sciences investment firm that backs companies in biotech, therapeutics, and healthcare innovation, with a focus on translating scientific research into transformative medicines and treating severe diseases.

1 investor

MS BIO develops products for the treatment and regeneration of damaged tissue using human tissue and biomaterials such as collagen. It works with clinical experts and corporate partners to research and develop these regenerative medicine products.

1 investor

MSD is a pharmaceutical company focused on developing medicines and vaccines for patients globally, guided by a science-led innovation strategy.

1 investor

MSICS Pharma develops naturally-sourced psilocybin products for pharmaceutical use, operating a GMP production facility that produces its flagship product MSX-06. The product is undergoing clinical trials with hospitals to treat mental health conditions including depression, OCD, anxiety, PTSD, and eating disorders.

1 investor

mTilda provides a Laboratory Information Management System (LIMS) for HLA laboratories, offering data management, analysis tools, and EMR integration. The company serves histocompatibility and immunogenetics labs with custom software solutions and implementation support.

1 investor

Mountain Group Partners is a venture capital firm with 25 years of history that invests in disruptive technologies, diagnostics, medtech, animal health, and drug development across underserved sectors. The firm operates with a long-term investment horizon and an operator-focused approach, maintaining significant co-investment in its funds.

1 investor

MucoLife Therapeutics develops treatments for pulmonary mucus obstruction associated with chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Its lead product is a mucus modulator designed to dissolve mucus plugs obstructing the airways.

1 investor

multimmune develops cancer diagnostics and therapeutics ("theranostics") based on membrane Hsp70, a molecule expressed across many cancer types. Its work spans therapeutic interventions, drug targeting strategies, diagnostic tools, and imaging platforms within precision oncology.

1 investor

MultiplAI Health is developing an RNA-sequencing and AI-based whole blood screening test to detect complex diseases, with a focus on cardiovascular disorders and cancer. The technology analyzes molecular RNA variances in blood to identify increased risk of cardiovascular events, aiming to enable routine remote screening.

1 investor